
Yen-Shen Lu
Advertisement
Articles by Yen-Shen Lu



30 Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously-Treated Inoperable or Metastatic Hormone Receptor–Positive, HER2-Negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri,Seock-Ah Im,Senia Pernas,Michelino De Laurentiis,Shusen Wang,Noelia Martínez Jañez,Giuliano Borges,David W. Cescon,Masaya Hattori,Yen-Shen Lu,Erika P. Hamilton, MD,Qingyuan Zhang,Junji Tsurutani,Kevin Kalinsky, MD, MS,Lu Xu,Neelima Denduluri,Binghe Xu,Barbara Pistilli


Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
2
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
5

